Session 1: Clinical Transi ons and Preven on of Hospital Readmissions C: Chronic Obstruc ve Pulmonary Disease 11:15am - 12:15pm
|
|
- Maryann Bates
- 5 years ago
- Views:
Transcription
1 January 20-22, 2012 Des Moines Marrio, 700 Grand Avenue, Des Moines, IA Session 1: Clinical Transi ons and Preven on of Hospital Readmissions C: Chronic Obstruc ve Pulmonary Disease 11:15am - 12:15pm ACPE UAN L01-P Ac vity Type: Applica on-based 0.1 CEU/1.0 Hr Program Objec ves for Pharmacists: Upon comple on of this CPE ac vity par cipants should be able to: 1. List preventable risk factors for hospital readmission for COPD 2. Describe mechanisms to prevent hospital readmissions for COPD related to medica on use 3. Recommend and defend pharmacotherapeu c interven ons to prevent high-risk pa ents from being rehospitalized for exacerba ons of COPD 4. Construct plans for monitoring effec ve medica on use in pa ents with COPD Speaker: Gary Milavetz, BS, PharmD, RPh, received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from the University of Minnesota. A er comple ng a Post-Doctoral clinical pharmacy fellowship in pediatric respiratory diseases, he was appointed to the faculty of the University of Iowa College of Pharmacy. Currently, he is an Associate Professor of Pharmacy and is also a clinical pharmacist in the Allergy and Pulmonary Division of the Department of Pediatrics at the University of Iowa Hospitals and Clinics. He sees pa ents, directs introductory and advanced prac ce student pharmacists and precepts pharmacy residents at the Pediatric Allergy and Pulmonary Clinics. He lectures in respiratory therapeu cs. His most recent research is in understanding driver impairment by therapeu c medica ons at the Na onal Advanced Driving Simulator on the University of Iowa campus. He is a Fellow of the American College of Clinical Pharmacy. Speaker Disclosure: Gary Milavetz does not report any actual or poten al conflicts of interest in rela on to this CPE ac vity. Off-label use of medica ons will not be discussed during this presenta on.
2 Clinical Transitions and Prevention of Hospital Readmissions: Chronic Obstructive Pulmonary Disease Faculty Disclosure Gary Milavetz reports no actual or potential conflicts of interest associated with this presentation. Gary Milavetz, BS, PharmD, FCCP Associate Professor The University of Iowa College of Pharmacy Gary Milavetz indicates that off label use of medications will be discussed during this presentation. Learning Objectives Upon completion of this activity participants will be able to: List risk factors for hospital readmission for COPD Describe medication interventions geared to prevent hospital re admissions for COPD. Recommend and support pharmacotherapeutic interventions to prevent high risk patients from being rehospitalized for exacerbations of COPD Construct plans for monitoring effective medication use in patients with COPD Pre Assessment Questions 1. What is the primary cause of COPD? A. Smoking B. Pollution C. Old age D. Chronic pulmonary infections 2. List primary pharmacotherapy for COPD A. Bronchodilators and corticosteroids B. Antibiotics and bronchodilators C. Antibiotics and corticosteroids D. Mucolytics and oxygen 3. Non pharmacologic therapy should include: A. Education B. Nutrition C. Physical activity Case vignette #1: Stubborn Stella CC: I got smothern spells again and don t bother telling me to stop smoking because I ain t gonna do it. Just let me catch my breath. HPI: 76 y.o. Caucasian female with a long history of COPD with exacerbations (4 6x/yr). She has SOB and coughs up several tablespoons of sputum several times a day. Respiratory symptoms have worsened over the past week. Coughing paroxysms result in her lips and nail beds getting dusky. History of smoking 1 ½ packs/day for about 60 years. Med Hx: Levalbuterol 1.25mg by nebulizer q4h. Combivent MDI prn (uses 4 6 x/day, last refill 3 weeks ago) Maxair Autohaler prn (uses 4 6x/day, last refill 3 weeks ago) Amoxicillin 250mg TID (filled 4 days ago) Why is COPD important? COPD is the 3 rd leading cause of death in the US In 2001, more than 12 million were diagnosed as having COPD * COPD costs US about $32.1B in 2002* Major cause of disability Patients are frequently hospitalized * international.com/library/statistics.htm Accessed 12/1/11 1
3 Chronic Obstructive Pulmonary Disease Two primary forms: Chronic bronchitis (inflamed airways) Emphysema (damaged alveoli) Most patients will have some combination of both Common symptoms Coughing with or without sputum production Wheezing Shortness of Breath (SOB) Dyspnea on Exertion (DOE) Frequent respiratory infections Develops over years to decades Causes of COPD Inhaled irritant exposure Primary cigarette smoke (#1 cause) Secondhand smoke Fire smoke without proper ventilation Chemicals, dust, other airborne particulates and pollution Treatment goals Slow or halt disease progression Reduce exposure to inhaled irritants Effectively treat acute symptoms Prevent exacerbations Allow normal lifestyle Treatment review Smoking cessation Education Pharmacotherapy Bronchodilators Glucocorticoids Inhaled Oral Others: Oxygen, antibiotics, mucolytics Physical activity Nutrition 2010 Global Initiative (GOLD) Update: accessed 12/1/11 Smoking cessation Pharmacotherapy Nicotine replacement Varenicline Bupropion Behavioral Slow reduction Cold turkey Substitution Alternative approaches Acupuncture Suggestion therapy Bronchodilators Methylxanthines Theophylline/aminophylline Others B 2 selective sympathomimetic agonists Short acting (for reversible component) Albuterol/levalbuterol Pirbuterol Long acting Salmeterol Formoterol/arformoterol Anticholinergics Ipratropium Tiotropium 2
4 Corticosteroids Inhaled (maintenance of asthmatic component) Beclomethasone Budesonide Ciclesonide Fluticasone Mometasone Oral (intervention) Prednisone/methylprednisone Hydrocortisone Dexamthasone Combination therapy ICS + LABA Advair (fluticasone + salmeterol) Symbicort (budesonide + formoterol) Dulera (mometasone + formoterol) Anticholinergic + SABA Combivent (albuterol + ipratropium) Pharmacotherapy: Other Antibiotics for evidence of a bacterial infection Depends on culture and sensitivity/local patterns Lack of evidence for use: BMC Medicine 2008, 6:28 Bacteria: H. influenzae, S. Pneumonia, M. catarrhalis Aminopenicillin (with or without clavulanic acid) Macrolide Tetracycline Mucolytics Dornase alfa (rhdnase) N acetylcysteine Oxygen Short term Long term Proper technique for inhaled medications Metered dose inhalers Valved holding chambers for MDIs Dry powder inhalers Nebulizers Non pharmacologic therapy Education Disease Treatment plan Nutrition Physical activity (Pulmonary rehabilitation) Individualized and gradual to reduce impairment Vaccinations Psychosocial support as needed Surgery? Case vignette #2: Chesterfield Chester Chester is a 66 yo retired machinist who has a 20 pack year history of smoking. He was admitted with an acute exacerbation of COPD and discharged after a 4 day tune up with the following prescriptions: Verenicline: 0.5mg qd x 3 days, then 0.5mg BID x 3 days then 1mg BID Tiotropium HandiHaler 1 capsule every day Azithromycin 500mg first day, now on day #3/5 of 250mg What other recommendations do you have? 3
5 What s the issue? COPD readmission rates (from AHRQ s H CUP database 1 ): Across 15 states in ,700 admissions with COPD as primary diagnosis 30 day readmission rate with COPD as primary diagnosis was 7.1% 30 day readmission rate with COPD for any diagnosis was 17.3% Costs were higher for readmissions Diabetes 30 day readmission range: % 2 What are the risk factors for readmissions? Previous hospital admission Dyspnea Oral corticosteroid use Long term O2 Low health status Poor health QoL No routine physical activity 1. us.ahrq.gov/reports/statbriefs/sb121.jsp accessed 12/1/ Am J Public Health 2005;95: Accessed 12/1/11 Bahadori and FitzGerald Int J of COPD 2007;2: Causes of COPD acute exacerbations Modifiable risk factors Smoking The most important activity to reduce progression of disease Physical inactivity Poor nutrition Fixed risk factors Underlying disease severity Can readmissions be prevented? Yes, with an integrated care approach Comprehensive assessment Education Individualized care plan Access to specialized nurse at hospital Primary care team consisted of physician, nurse and social worker Garcia Aymerich et al Resp Med 2007;101: Integrated care to prevent readmissions Includes: Patient education Coordination of care amongst caregivers Improves: Patient compliance Exercise capacity Health related QoL Reduces: Hospital readmissions But not mortality Pharmacists role in preventing COPD readmissions Assure patients are on appropriate treatments Assess adherence at refills Assure patients can use devices Educate on medication use and treatment plans Encourage exercise Encourage good nutrition Conduct discharge counseling and follow up post hospitalizations Provide MD with all info regarding Rx use at hospitalization Facilitate smoking cessation Evaluate vaccination status and provide where needed Spirometry? 4
6 Coughing Karl 69 year old male is admitted for an acute exacerbation of COPD. Quit smoking cigarettes 4 years ago. Primary symptom on admission was coughing and unable to catch his breath. In the hospital he was treated with continuous albuterol nebulization until his peak flows returned to his prior best. He is discharged after 4 days in the hospital on the following medications: Albuterol inhalant solution one vial by nebulizer prn Salmeterol diskus one inhalation BID Combivent MDI 2 puffs QID Ipatropium 2 puffs q6h and up to twice more prn Return to Pulmonary clinic in 3 months What are the drug therapy problems? What else does Karl need? Post Assessment Questions An integrated care approach to COPD includes which of the following? [Please insert post assessment questions here & discuss answers with participants to allow them to self assess their learning of the information. These questions will also be included as the online exam which is required (with passing grade of 70%>) to receive CPE credit] Continuing Pharmacy Education Go to click on My Portfolio Scroll down to Take Exam Enter Access Code: (case sensitive) Pharmacists Technicians 5
7 2012 Educational Expo Chronic Obstructive Pulmonary Disease Gary Milavetz, BS, PharmD, RPh Post Assessment Questions 1. Which of the following best describes COPD disease progression? A. Complete reversibility of airway obstruction B. Gradual and progressive destruction of pulmonary tissue C. Thickening of alveolar capillary membranes reducing gas exchange D. Respiratory muscle fatigue resulting in reduced breathing effort 2. Which of the following is a COPD treatment goal A. Slow or halt disease progression B. Treat acute symptoms C. Prevent exacerbations D. All of the above 3. Treatment of COPD includes which of the following? A. Smoking cessation B. Pharmacotherapy C. Physical activity regimen D. All of the above 4. Metered dose inhaler technique differs from dry powder inhaler technique by which of the following actions? A. MDIs require a slow deep breath while DPIs require a rapid deep breath B. MDIs require a longer time to hold breath C. DPIs allow an open mouth inhalation D. DPIs must be shaken before dose is administered 5. Valved holding chambers have which of the following advantages? A. Hold aerosolized dose in chamber for up to five minutes B. Separate MDI actuation from inspiration C. May be used with nebulizers D. Reduces drug delivery time
8 Clinical Transitions and Prevention of Hospital Readmissions COPD Coughing Karl 69 year old male is admitted for an acute exacerbation of COPD. Quit smoking cigarettes 4 years ago. Primary symptom on admission was coughing and unable to catch his breath. In the hospital he was treated with continuous albuterol nebulization until his peak flows returned to his prior best. He was discharged after 4 days in the hospital on the following medications with treatment plan: Albuterol inhalant solution by nebulizer prn What went wrong? (Assessment) Patient problems: System problems: Salmeterol diskus one inhalation BID Combivent MDI 2 puffs QID Ipatropium 2 puffs q6h and up to twice more prn Return to Pulmonary clinic in 3 months Intervention: (Plan) What drug therapy problems can you identify? What else does Karl need?
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationWomen Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationWomen Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationBreaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More
Breaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More Char Raley, RRT Brandon Johnson, PharmD, BCPS Pulmonary and Critical Care Symposium June 12 th, 2015 We have had no
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationCOPD Treatable. Preventable.
My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationDebating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2
Debating the use of inhaled corticosteroids in the treatment of COPD Suzanne G. Bollmeier Pharm.D., BCPS, AE-C Associate Professor, St. Louis College of Pharmacy ACPE Guidelines on Non- Commercialism o
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationAssessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)
William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging
More informationHow can I benefit most from my COPD medications?
Fact Sheet: COPD Medications and Delivery Devices How can I benefit most from my COPD medications? COPD medications can improve your symptoms. By taking the right medication at the right time, you can
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationTECH TALK CE THE NATIONAL CONTINUING EDUCATION PROGRAM FOR PHARMACY TECHNICIANS
Instructions 1 CEU FREE CE FOR TECHNICIANS Tech Talk CE is Canada s first and only continuing education correspondence program specifically designed for technicians. It s brought to you by the publishers
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationA patient educational resource provided by Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any other organization that advertises or markets its disease management products and services. A patient educational resource provided
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationUNDERSTANDING & MANAGING
UNDERSTANDING & MANAGING YOUR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)* *Includes chronic bronchitis, emphysema, or both Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any
More informationCOPD Education for Clinic RNs and MA s 6/28/18
COPD Education for Clinic RNs and MA s 6/28/18 Objectives Define Chronic Obstructive Disease (COPD) Diagnosis of COPD Review recommended therapies for COPD. Teach-Back OSA and it s impact. I want to interact
More informationACO Impact on Transitions of Care: Witnessing the Improved Value of Re Engineering Communication at All Points of Care
ACO Impact on Transitions of Care: Witnessing the Improved Value of Re Engineering Communication at All Points of Care Christopher B Cooper, MD Professor of Medicine and Physiology David Geffen School
More informationOverview of COPD INTRODUCTION
Overview of COPD INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a common lung disease that affects millions of people, and it is the fourth leading cause of death in the United States. It
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationWhat You Need to Know about Metered-Dose Inhalers and the HFA Propellant
What You Need to Know about Metered- Inhalers and the HFA Propellant There are a number ways to deliver inhaled medication. They include: Metered-dose inhaler () Metered-dose inhaler with spacer/holding
More informationCommon Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationHistory & Development
RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species
More informationPeople with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.
COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationBackground. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationCough Associated with Bronchitis
Cough Associated with Bronchitis Bronchitis (bron-ki-tis) is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. People who have bronchitis often have a cough
More informationSalford COPD Treatment Pathway
Salford COPD Treatment Pathway Development led by Helen Pyne with Salford Asthma and Respiratory Team (SART) Department Respiratory Medicine Salford Royal NHS Foundation Trust Hope Hospital, Stott Lane,
More informationChronic Obstructive Pulmonary Disease
Scope of Problem Chronic Obstructive Pulmonary Disease Marianne J. Davies, RN, MSN, APRN Yale University School of Medicine Yale Comprehensive Cancer Center Nevada Cancer Institute 2005 Hospitalizations
More informationClinical Guideline for the Diagnosis, Evaluation, and Management of Adults and Children with Asthma
Clinical Guideline for the Diagnosis, Evaluation, and Management of Adults and Children with Asthma - 2005 Criteria that suggest the diagnosis of Asthma: The symptoms of dyspnea, cough and/or wheezing,
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 9 PURPOSE To assure that DOP inmates with Pulmonary Diseases are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers and Chronic Disease Nurses are
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationWhat is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018
What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018 No disclosures Disclosures objectives How to diagnose & Assess severity Treatment: Pharmacologic Non-Pharmacologic Maintenance
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationCOPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?
Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationSample. Affix patient label within this box.
Instructions for completing orders Complete pages 1-3 for General Inpatient Orders. All pathway compatible orders (indicated by ) within the General Inpatient Orders will be followed automatically. Optional
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationMANAGING COPD AT HOME. Karla Schlichtmann, RRT
MANAGING COPD AT HOME Karla Schlichtmann, RRT Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease. WHAT IS COPD? The airways in your lungs become inflamed and thickens. This results
More informationPeak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation
Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation PI: Brian Driver, MD Checklist Reviewed Inclusion and Exclusion Criteria Confirm pertinent exclusion criteria with PMP Engage
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationCOPD. Definitionn. make. when (bronchioles) in. the lungs. Wheezing Chest tightness. your lungs. greenish. Lack of energy
COPD Definitionn Emphysema and chronic bronchitis are the two most common conditions thatt make up COPD. Chronic bronchitis is an inflammation of the lining of your bronchial tubes, which carry air to
More informationAsthma Education. The Keys to Asthma Prevention and Control. what to do when one s asthma is flared! Lucile Packard Children s Hospital.
Asthma Education Lucile Packa r d Children s H o spit al Created by Rachel Lawler RN, MSN, cpnp, AE-C, NPAT Pulmonary Pediatric Nurse Practitioner Lucile Packard Children s Hospital The Keys to Asthma
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationPulmonary Pathway & Assessment/Plan of Care: Acute. Pulmonary Risk Factors & Pulmonary History
Pulmonary Risk Factors & Pulmonary History Pulmonary History: Asthma Bronchitis COPD Emphysema Cystic Fibrosis Pneumonia (last 30d) Other: Smoking: Never Current Cigs/Day Previous Year Quit Alcohol Use
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward
More informationAsthma COPD Update 2018
Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State
More informationASTHMA PROTOCOL CELLO
ASTHMA PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives, non medical and medical therapy and a scheme for inhaler dosage.
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationAnyone who smokes and/or has shortness of breath and sputum production could have COPD
COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationYour Inhaler Devices & You
1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE
More information